Dr. Liza C. Villaruz
Claim this profileUniversity of Pittsburgh Cancer Institute (UPCI)
Expert in Lung Cancer
Expert in Non-Small Cell Lung Cancer
37 reported clinical trials
53 drugs studied
About Liza C. Villaruz
Education:
- Obtained MD from the University of Pittsburgh School of Medicine in 2010.
- Completed Residency in Radiation Oncology at the University of Pittsburgh Medical Center in 2015.
- Finished Fellowship in Radiation Oncology at the University of Pittsburgh Cancer Institute in 2016.
Experience:
- Assistant Professor of Radiation Oncology at the University of Pittsburgh School of Medicine.
- Radiation oncologist at the University of Pittsburgh Cancer Institute, with a specialization in breast cancer and gastrointestinal malignancies.
Area of expertise
1Lung Cancer
Global LeaderStage IV
Stage III
Stage II
2Non-Small Cell Lung Cancer
Global LeaderStage IV
Stage III
Stage II
Affiliated Hospitals
Clinical Trials Liza C. Villaruz is currently running
CAB-ROR2-ADC + PD-1 Inhibitor
for Breast Cancer
This trial is testing a new targeted cancer treatment called CAB-ROR2-ADC in patients with advanced solid tumors. The drug seeks out cancer cells with a specific marker and delivers a potent treatment directly to them.
Recruiting1 award Phase 1 & 29 criteria
Crizotinib
for Non-Small Cell Lung Cancer
This randomized phase III trial studies how well crizotinib works in treating patients with stage IB-IIIA non-small cell lung cancer that has been removed by surgery and has a mutation in a protein called anaplastic lymphoma kinase (ALK). Mutations, or changes, in ALK can make it very active and important for tumor cell growth and progression. Crizotinib may stop the growth of tumor cells by blocking the ALK protein from working. Crizotinib may be an effective treatment for patients with non-small cell lung cancer and an ALK fusion mutation.
Recruiting2 awards Phase 328 criteria
More about Liza C. Villaruz
Clinical Trial Related5 years of experience running clinical trials · Led 37 trials as a Principal Investigator · 16 Active Clinical TrialsTreatments Liza C. Villaruz has experience with
- Pembrolizumab
- Carboplatin
- Atezolizumab
- Pemetrexed
- Berzosertib
- Gemcitabine Hydrochloride
Breakdown of trials Liza C. Villaruz has run
Lung Cancer
- Pilot Immunotherapy Study With Letetresgene Autoleucel (Lete-cel, GSK3377794)T-cells in New York Esophageal Squamous Cell Carcinoma-1 (NY-ESO-1)/ LAGE-1a-positive Advanced Non-small Cell Lung Cancer (NSCLC) Either Alone or in Combination With Pembrolizumab
- A Study Osimertinib in Patients With Stage 4 Non-small Cell Lung Cancer With Uncommon EGFR Mutations
- Atezolizumab + Cobimetinib for Lung Cancer
Non-Small Cell Lung Cancer
- Pilot Immunotherapy Study With Letetresgene Autoleucel (Lete-cel, GSK3377794)T-cells in New York Esophageal Squamous Cell Carcinoma-1 (NY-ESO-1)/ LAGE-1a-positive Advanced Non-small Cell Lung Cancer (NSCLC) Either Alone or in Combination With Pembrolizumab
- A Study Osimertinib in Patients With Stage 4 Non-small Cell Lung Cancer With Uncommon EGFR Mutations
- Atezolizumab + Cobimetinib for Lung Cancer
Cancer
- M6620 + Topotecan for Small Cell Lung Cancer
- Atezolizumab + Cobimetinib for Lung Cancer
- Testing the Addition of an Anti-cancer Drug, Entinostat, to the Usual Chemotherapy and Immunotherapy Treatment (Atezolizumab, Carboplatin and Etoposide) for Previously Untreated Aggressive Lung Cancer That Has Spread
Tumors
- Pilot Immunotherapy Study With Letetresgene Autoleucel (Lete-cel, GSK3377794)T-cells in New York Esophageal Squamous Cell Carcinoma-1 (NY-ESO-1)/ LAGE-1a-positive Advanced Non-small Cell Lung Cancer (NSCLC) Either Alone or in Combination With Pembrolizumab
- Testing the Addition of an Anti-cancer Drug, Entinostat, to the Usual Chemotherapy and Immunotherapy Treatment (Atezolizumab, Carboplatin and Etoposide) for Previously Untreated Aggressive Lung Cancer That Has Spread
- M6620 + Irinotecan for Cancer
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Liza C. Villaruz specialize in?
Liza C. Villaruz focuses on Lung Cancer and Non-Small Cell Lung Cancer. In particular, much of their work with Lung Cancer has involved Stage IV patients, or patients who are Stage III.
Is Liza C. Villaruz currently recruiting for clinical trials?
Yes, Liza C. Villaruz is currently recruiting for 16 clinical trials in Pittsburgh Pennsylvania. If you're interested in participating, you should apply.
Are there any treatments that Liza C. Villaruz has studied deeply?
Yes, Liza C. Villaruz has studied treatments such as Pembrolizumab, Carboplatin, Atezolizumab.
What is the best way to schedule an appointment with Liza C. Villaruz?
Apply for one of the trials that Liza C. Villaruz is conducting.
What is the office address of Liza C. Villaruz?
The office of Liza C. Villaruz is located at: University of Pittsburgh Cancer Institute (UPCI), Pittsburgh, Pennsylvania 15232 United States. This is the address for their practice at the University of Pittsburgh Cancer Institute (UPCI).
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.